Human cancer is characterized by genetic and epigenetic alterations. In this study we provide evidence for the interruption of Ras signaling in sporadic colorectal cancer (CRC) by either genetic activation of the K-ras oncogene or epigenetic silencing of the putative tumor suppressor gene RASSF1A. Paran embedded tumor tissue samples from 222 sporadic CRC patients were analysed for K-ras codon 12 and codon 13 activating mutations and RASSF1A promoter hypermethylation. Overall, K-ras mutations were observed in 87 of 222 (39%) and RASSF1A methylation was observed in 45 of 222 (20%) of CRCs. Mutation of K-ras alone was detected in 76 of 222 (34%) CRCs. RASSF1A promoter methylation with wild-type K-ras was observed in 34 of 222 (15%) CRCs. In 101 of 222 (46%) CRCs neither Kras mutations nor RASSF1A methylation was observed and 11 of 222 (5%) CRCs showed both K-ras mutations and RASSF1A methylation. These data show that the majority of the studied CRCs with K-ras mutations lack RASSF1A promoter methylation, an event which occurs predominantly in K-ras wild-type CRCs (P=0.023, Chisquare test).
The Ras family of small GTPases includes three highly similar p21 proteins: H-, K-and N-ras, which are encoded by dierent genes and which function as molecular switches in cell proliferation, dierentiation and apoptosis signal transduction pathways (Campbell et al., 1998; Crespo and Leon, 2000) . Ras proteins, which are located at the inner plasma membrane, are activated transiently as response to extracellular signals such as growth factors, cytokines and hormones that stimulate cell surface receptors (Campbell et al., 1998) . The biological activity of Ras proteins is mediated by an eector domain, by which these proteins bind to dierent eector molecules (Campbell et al., 1998; Crespo and Leon, 2000; Shields et al., 2000) . The hallmark of Ras function is a transition between an inactive state, in which the proteins are bound to GDPs and an active state in which conversion to GTPs occurs. This transit is governed by two types of regulatory proteins: guanine nucleotide exchange factors which catalyze the GDP/GTP exchange and GTPase-activating proteins which enhance the intrinsic capacity of Ras proteins to hydrolyze GTP into GDP, thereby returning Ras to the inactive state (Crespo and Leon, 2000) .
Mutant, activated forms of Ras proteins, which are frequently observed in cancer, have an impaired GTPase activity rendering the protein resistant to inactivation by regulatory GAP proteins (Bos, 1989; Crespo and Leon, 2000) . Known activating mutations are mainly found in codons 12 and 13, and to a lesser extent in codons 59, 61 and 63. The frequency of each ras oncogene in tumors varies, depending on the tissue of origin for the neoplasia. H-ras mutations are preferentially found in cancers of the skin and in squamous head and neck tumors, whereas N-ras mutations are common in hematopoietic malignancies. K-ras mutations are mainly detected in adenocarcinomas of the lung, pancreatic carcinomas and CRCs (Rodenhuis, 1992) .
Recently a new Ras eector homologue was characterized (Dammann et al., 2000) named RASSF1, which is located at chromosome 3p21.3, a region frequently showing allelic loss in many cancers (Kok et al., 1997) . The gene for RASSF1 encodes two major transcripts, RASSF1A and RASSF1C, which are produced by alternative, CpG island containing promoters and alternative mRNA splicing. The C splice variant of RASSF1 binds Ras in a GTPdependent manner and mediates the apoptotic eects of oncogenic Ras (Vos et al., 2000) . RASSF1C expression is reduced in ovarian tumor cell lines (Vos et al., 2000) , but not in breast, lung and kidney cancer cell lines (Burbee et al., 2001; Dreijerink et al., 2001 ). The RASSF1A isoform, which shows homology with the Ras eector Nore 1, has a putative ATM phosphorylation site and binds to the DNA repair protein XPA, which suggests it is involved in DNA repair and cell cycle control Dammann et al., 2000) .
Promoter methylation of RASSF1A and subsequent reduction of expression has been recently reported in a very high proportion of small cell lung cancer (Damman et al., 2001a) and nasopharyngeal cancer (Lo et al., 2001) and to a lesser degree in non small cell lung cancers (Dammann et al., 2000) , bladder cancer , breast cancer Burbee et al., 2001; Dammann et al., 2001b) , ovarian cancer Yoon et al., 2001) , renal cell carcinoma (Dreijerink et al., 2001; Morrissey et al., 2001; Yoon et al., 2001 ) and gastric cancer . Although not studied simultaneously in the same tumors, the highest incidence of RASSF1A methylation is observed in tumor types with infrequent ras gene mutations, i.e. small cell lung cancer and nasopharyngeal cancer (Bos, 1989) . This is consistent with observations that simultaneously occurring (epi)genetic alterations of genes in the same signaling pathway are seldomly observed in a single tumor. For example, mutations in the regulatory domain of b-catenin and APC gene were observed to be mutually exclusive in CRC, consistent with their similar eects on b-catenin stability and Tcf activation (Sparks et al., 1998) . Furthermore, simultaneous inactivation of Rb and the p16
INK4a locus, which negatively regulates the phosphorylation of Rb, is rarely found in any tumor type (Serrano, 1997) .
To test whether this association also holds true for the Ras signaling pathway, we examined K-ras mutations and RASSF1A promoter methylation in sporadic CRC (n=222), a cancer type with a relatively high frequency (40%) of K-ras mutations (Rodenhuis, 1992) . We detected K-ras mutations in 87 of 222 (39%) CRCs, a frequency consistent with previous reports on the mutational frequency in primary colon cancer. Examples of K-ras sequencing are shown in Figure 1 . We did not observe any association of K-ras mutation with age at diagnosis, gender, Dukes stage or location of the tumor (Table 1) .
From our hypothesis that K-ras gene mutations and RASSF1A methylation are mutually exclusive, it would be predicted that the frequency of RASSF1A methylation in primary CRCs would be lower than the frequencies observed in tumor types which rarely show ras gene mutations (Bos, 1989; Rodenhuis, 1992) , i.e. primary small cell lung cancer (71 ± 79%) Burbee et al., 2001; Dammann et al., 2001a) , breast cancer (49 ± 62%) (Burbee et al., 2001; Dammann et al., 2001b) , renal cell carcinoma (23 ± 91% (Dreijerink et al., 2001; Morrissey et al., 2001; Yoon et al., 2001 ) nasopharyngeal cancer (67%) (Lo et al., 2001) , bladder cancer (35 ± 62%) Maruyama et al., 2001 ) and neuroblastoma (55%) .
To study RASSF1A methylation, MSP primers were located in the 5' region of this gene, where methylation has been previously observed and tested by analysing the lung cancer cell line A549 as a methylated control (Dammann et al., 2000) . DNA from normal breast tissue (n=4), normal lung tissue (n=4) and normal lymphocytes (n=3) was also examined for methylation changes in this region. The A549 cell line was fully methylated for RASSF1A, while DNA from normal lymphocytes, normal breast and normal lung tissue was unmethylated (Figure 2) .
In CRC, RASSF1A methylation was observed in 45 of 222 (20%) of the tumors. Examples of the RASSF1A MSP are shown in Figure 2a . We also analysed DNA from normal colon tissue obtained from six non-cancer patients. None of the six tissues showed RASSF1A methylation (Figure 2b ). In addition to tissue from non-cancer patients, DNA from normal colon epithelium microdissected from seven CRCs was analysed. In six of seven cases, normal colon DNA was Figure 1 Representative examples of the sequence analysis of codon 12 and 13 of the K-ras gene of three CRCs. Mutations were analysed by direct sequencing. First, a¯anking PCR product of 179 bp was ampli®ed (annealing temperature 588C) using the primers 5'-AGG CCT GCT GAA AAT GAC TGA ATA-3' (sense primer) and 5'-CTG TAT CAA AGA ATG GTC CTG CAC-3' (antisense primer). The resulting fragment was then used as a template to amplify a 114 bp fragment including codon 12 and codon 13 using the primers 5'-AAA ATG ACT GAA TAT AAA CTT GTG G-3' (sense primer) and 5'-CTC TAT TGT TGG ATC ATA TTC GTC-3' (antisense primer). This PCR was performed using one standard and one biotinylated primer, the annealing temperature was 508C. The PCR product is then captured on a sequencing comb coated with streptavidin (AutoLoad Solid Phase Sequencing Kit, Amersham Pharmacia Biotech), and the non-biotinylated strand is removed by alkaline denaturation. The remaining immobilized strand serves as the template for dideoxy sequencing reactions using a Cy5 labeled primer (5'-CTC TAT TGT TGG ATC ATA TTC GTC CAC-3') and T7 DNA polymerase (procedure according to manufacturers instructions) and is analysed on the ALFexpress II DNA Analysis System using ALFwin Administration software (Amersham Pharmacia Biotech). CRC 124 shows a G to C mutation (MUT) at the second base of codon 12, CRC 132 shows a G to A mutation at the second base of codon 13 and CRC 151 is wildtype (WT) for K-ras codons 12 and 13. The presence of a wildtype sequence in CRCs 124 and 132 is probably the result of the presence of normal, contaminating tissue unmethylated for RASSF1A. In one case, DNA isolated from normal colon tissue showed RASSF1A methylation. This patient also had RASSF1A methylation in DNA obtained from adjacent tumor tissue (Figure 2b ). RASSF1A methylation in this`normal' colon tissue might be explained by the presence of contaminating tumor cells or the presence of a ®eld defect in colon mucosa.
As observed for K-ras mutations, RASSF1A methylation was not associated with gender, Dukes stage and location of the tumor (Table 1 ). Age at diagnosis was slightly higher (P=0.033, T test) in RASSF1A methylated CRCs. RASSF1A methylation, however, was largely con®ned to tumors without K-ras mutations. RASSF1A promoter methylation without K-ras mutations was observed in 34 of 222 (15%) CRCs, while 76 of 222 (34%) CRCs showed K-ras gene mutations without RASSF1A promoter methylation. This dierence between methylation of RASSF1A versus K-ras mutations was statistically signi®cant (P=0.023, two-tailed Chi square test).
Since the majority of mutations in K-ras occur in codons 12 and 13, inclusion of codons 59, 61 and 63 in the K-ras gene analysis would not be expected to increase the prevalence of K-ras mutations in this study signi®cantly. Therefore, our observation that 46% (101 of 222) of the CRCs contain neither K-ras codon 12 and 13 mutations nor RASSF1A methylation, suggest that other genes in the Ras signal transduction pathway may be altered in CRC. Alternatively, Ras signaling may not be aected in all CRCs.
A small proportion (11/222 (5.0%)) of CRCs had both RASSF1A methylation and K-ras mutations. These CRCs did not show speci®c characteristics concerning type of mutations of clinico-pathological parameters. Redundancy in alterations of members of the same pathway is sometimes observed, i.e. p14 ARF methylation and p53 mutations (Esteller et al., 2000) . One explanation is that the coexistance of alterations Figure 2 Representative examples of RASSF1A MSP reactions of six primary CRCs (a) and of DNA isolated from normal colon epithelium of four CRC patients and two non-cancer patients (b). DNA methylation in the CpG island of RASSF1A was determined by chemical modi®cation of genomic DNA with sodium bisul®te and subsequent MSP as described elsewhere (Herman et al., 1996) . The primers used were 5'-GTT TAG TTT GGA TTT TGG GGG AG-3' (sense primer) and 5'-CCC RCA ACT CAA TAA ACT CAA ACT C-3' (antisense primer). The annealing temperature was 568C. The resulting 144 bp fragment was used as a template for the MSPreaction. Primer sequences for the unmethylated reaction were 5'-GGG GTT TGT TTT GTG GTT TTG TTT-3' (sense primer) and 5'-AAC ATA ACC CAA TTA AAC CCA TAC TTC A-3' (antisense primer). Primer sequences for the methylated reaction were 5'-GGG TTC GTT TTG TGG TTT CGT TC-3' (sense primer) and 5'-TAA CCC GAT TAA ACC CGT ACT TCG-3' (antisense primer). All PCRs were performed with controls for unmethylated RASSF1A alleles (DNA from normal lymphocytes), methylated RASSF1A alleles (normal lymphocyte DNA treated in vitro with Sssl methyltransferase (New England Biolabs)) and a negative control without DNA. The annealing temperature was 608C. 10 ml of each PCR reaction was directly loaded onto a nondenaturing 6% polyacrylamide gel, stained with ethidium bromide and visualized under UV illumination. The presence of a visible PCR product in those lanes marked U indicates the presence of unmethylated RASSF1A alleles; the presence of product in those lanes marked M indicates the presence of methylated alleles. All CRCs include ampli®cation with the U primer set, probably a result of the presence of normal, contaminating tissue. Normal lymphocytes (NL) and in vitro methylated DNA (IVD) were used as negative and positive controls for RASSF1A promoter methylation, respectively. The H 2 O control was included in the¯anking PCR and subsequently in the RASSF1A MSP Table 1 Clinico=pathological parameters of K-ras wildtype (WT) and mutant (MUT) and RASSF1A unmethylated (U) and methylated (M) CRCs and of the total group of CRCs of both RASSF1A and K-ras is a rare, stochastic event.
Alternatively, this could suggest that methylation of RASSF1A and mutational activation of K-ras are not functionally equivalent. While the frequency of RASSF1A methylation has been reported for many dierent types of cancer, little data concerning the function of this gene has been published. Exogenous expression of RASSF1A cell lines lacking expression decreased in vitro colony formation and in vivo tumorigenicity (Burbee et al., 2001; Dammann et al., 2000) . No studies have examined whether RASSF1A inactivation leads to constitutive activation of the Ras signaling pathway. However, our data provide further evidence for a role in cancer in that inactivation of RASSF1A occurs predominantly in CRCs without alteration of K-ras itself, and may provide an alternative pathway for aecting Ras signaling. The factors responsible for whether a cell will exhibit DNA methylation changes, gene mutations or allelic losses need to be clari®ed, although dierent exposures to environmental carcinogens might contribute to these dierences.
